202 related articles for article (PubMed ID: 11551516)
1. Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples.
Baker JR; Satarug S; Reilly PE; Edwards RJ; Ariyoshi N; Kamataki T; Moore MR; Williams DJ
Biochem Pharmacol; 2001 Sep; 62(6):713-21. PubMed ID: 11551516
[TBL] [Abstract][Full Text] [Related]
2. Activation of phenacetin O-deethylase activity by alpha-naphthoflavone in human liver microsomes.
Nakajima M; Kobayashi K; Oshima K; Shimada N; Tokudome S; Chiba K; Yokoi T
Xenobiotica; 1999 Sep; 29(9):885-98. PubMed ID: 10548449
[TBL] [Abstract][Full Text] [Related]
3. Escherichia coli MTC, a human NADPH P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450 isoforms 1A1, 1A2, 2A6, 3A4, or 3A5: catalytic activities and mutagenicity studies.
Kranendonk M; Carreira F; Theisen P; Laires A; Fisher CW; Rueff J; Estabrook RW; Vermeulen NP
Mutat Res; 1999 Apr; 441(1):73-83. PubMed ID: 10224324
[TBL] [Abstract][Full Text] [Related]
4. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
6. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
[TBL] [Abstract][Full Text] [Related]
7. Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase.
Fujita K; Kamataki T
Mutat Res; 2001 Nov; 483(1-2):35-41. PubMed ID: 11600130
[TBL] [Abstract][Full Text] [Related]
8. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.
Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW
Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470
[TBL] [Abstract][Full Text] [Related]
10. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece.
Dalekos GN; Makri E; Loges S; Obermayer-Straub P; Zachou K; Tsikrikas T; Schmidt E; Papadamou G; Manns MP
Eur J Gastroenterol Hepatol; 2002 Jan; 14(1):35-42. PubMed ID: 11782573
[TBL] [Abstract][Full Text] [Related]
11. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
Taavitsainen P; Juvonen R; Pelkonen O
Drug Metab Dispos; 2001 Mar; 29(3):217-22. PubMed ID: 11181487
[TBL] [Abstract][Full Text] [Related]
12. Cyp2a6 is a principal enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in humans.
Kimura M; Yamazaki H; Fujieda M; Kiyotani K; Honda G; Saruwatari J; Nakagawa K; Ishizaki T; Kamataki T
Drug Metab Dispos; 2005 Sep; 33(9):1361-6. PubMed ID: 15980104
[TBL] [Abstract][Full Text] [Related]
13. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16alpha-hydroxylation of 17beta-estradiol.
Badawi AF; Cavalieri EL; Rogan EG
Metabolism; 2001 Sep; 50(9):1001-3. PubMed ID: 11555828
[TBL] [Abstract][Full Text] [Related]
14. Biotransformation of parathion in human liver: participation of CYP3A4 and its inactivation during microsomal parathion oxidation.
Butler AM; Murray M
J Pharmacol Exp Ther; 1997 Feb; 280(2):966-73. PubMed ID: 9023313
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole.
Ueng YF; Hsieh CH; Don MJ
Food Chem Toxicol; 2005 May; 43(5):707-12. PubMed ID: 15778010
[TBL] [Abstract][Full Text] [Related]
16. Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver.
Chang TK; Chen J; Pillay V; Ho JY; Bandiera SM
Toxicol Sci; 2003 Jan; 71(1):11-9. PubMed ID: 12520071
[TBL] [Abstract][Full Text] [Related]
17. Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
Gorski JC; Jones DR; Wrighton SA; Hall SD
Biochem Pharmacol; 1994 Jul; 48(1):173-82. PubMed ID: 8043020
[TBL] [Abstract][Full Text] [Related]
18. Changes in zinc and copper homeostasis in human livers and kidneys associated with exposure to environmental cadmium.
Satarug S; Baker JR; Reilly PE; Moore MR; Williams DJ
Hum Exp Toxicol; 2001 Apr; 20(4):205-13. PubMed ID: 11393274
[TBL] [Abstract][Full Text] [Related]
19. Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP.
Kamataki T; Fujita K; Nakayama K; Yamazaki Y; Miyamoto M; Ariyoshi N
Drug Metab Rev; 2002 Aug; 34(3):667-76. PubMed ID: 12214673
[TBL] [Abstract][Full Text] [Related]
20. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
